NCT01806675 - 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 4, 2013

Primary Completion Date

December 7, 2016

Study Completion Date

April 30, 2019

Conditions

Adult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaMale Breast CancerMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Adenoid Cystic Carcinoma of the Oral CavityRecurrent Adult Brain TumorRecurrent Basal Cell Carcinoma of the LipRecurrent Colon CancerRecurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal CavityRecurrent Hypopharyngeal CancerRecurrent Inverted Papilloma of the Paranasal Sinus and Nasal CavityRecurrent Laryngeal CancerRecurrent Lip and Oral Cavity CancerRecurrent Lymphoepithelioma of the NasopharynxRecurrent Lymphoepithelioma of the OropharynxRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal CavityRecurrent Mucoepidermoid Carcinoma of the Oral CavityRecurrent Nasopharyngeal CancerRecurrent Non-small Cell Lung CancerRecurrent Oropharyngeal CancerRecurrent Pancreatic CancerRecurrent Paranasal Sinus and Nasal Cavity CancerRecurrent Rectal CancerRecurrent Renal Cell CancerRecurrent Salivary Gland CancerStage IIIA Breast CancerStage IIIA Non-small Cell Lung CancerStage IIIB Breast CancerStage IIIB Non-small Cell Lung CancerStage IIIC Breast CancerStage IV Breast CancerStage IV Non-small Cell Lung CancerStage IV Pancreatic CancerStage IV Renal Cell CancerStage IVA Colon CancerStage IVA Rectal CancerStage IVA Salivary Gland CancerStage IVB Colon CancerStage IVB Salivary Gland CancerStage IVC Salivary Gland CancerTongue CancerUnspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

18F-fludeoxyglucose (18F-FDG)

18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan

DRUG

18F-FPPRGD2

18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.

Trial Locations (1)

94305

Stanford University, School of Medicine, Stanford

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Sanjiv Sam Gambhir

OTHER